Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2025,
Carl Zeiss Meditec AG paidCHF0 Mil more to buy back shares than it received from issuing new shares.
It receivedCHF0 Mil from issuing more debt.
It paidCHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedCHF0 Mil from paying cash dividends to shareholders.
It receivedCHF0 Mil on other financial activities.
In all, Carl Zeiss Meditec AGspentCHF0 Mil on financial activities for the
three
months ended in Dec. 2025.
Carl Zeiss Meditec AG (XSWX:AFX) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Carl Zeiss Meditec AG's issuance of stock for the
three
months ended in Dec. 2025 was CHF0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Carl Zeiss Meditec AG's repurchase of stock for the
three
months ended in Dec. 2025 was CHF0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Carl Zeiss Meditec AG's net issuance of debt for the
three
months ended in Dec. 2025 was CHF0 Mil.
Carl Zeiss Meditec AG receivedCHF0 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Carl Zeiss Meditec AG's net issuance of preferred for the
three
months ended in Dec. 2025 was CHF0 Mil.
Carl Zeiss Meditec AG paidCHF0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Carl Zeiss Meditec AG's cash flow for dividends for the
three
months ended in Dec. 2025 was CHF0 Mil.
Carl Zeiss Meditec AG receivedCHF0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Carl Zeiss Meditec AG's other financing for the
three
months ended in Dec. 2025 was CHF0 Mil.
Carl Zeiss Meditec AG receivedCHF0 Mil on other financial activities.
Carl Zeiss Meditec AG Cash Flow from Financing Related Terms
Carl Zeiss Meditec AG Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Carl Zeiss Meditec AG's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG Cash Flow from Financing Chart
Carl Zeiss Meditec AG Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Carl Zeiss Meditec AG's Cash from Financing for the fiscal year that ended in Sep. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-165 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of CHF-165 Mil mean?
Carl Zeiss Meditec AG (XSWX:AFX) has a Cash Flow from Financing of CHF-165 Mil as of Dec. 2025. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Carl Zeiss Meditec AG and its competitors.
Is Carl Zeiss Meditec AG's Cash Flow from Financing too high?
Carl Zeiss Meditec AG's current Cash Flow from Financing is CHF-165 Mil. Overall, Carl Zeiss Meditec AG has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's Cash Flow from Financing compare to ISRG and BDX?
Carl Zeiss Meditec AG's Cash Flow from Financing of CHF-165 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Carl Zeiss Meditec AG and its competitors. Carl Zeiss Meditec AG's current Cash Flow from Financing is CHF-165 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF314.46, compared to a current price of CHF25.86 — trading 91.8% below its estimated fair value. The current Cash Flow from Financing is CHF-165 Mil. Carl Zeiss Meditec AG's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current Cash Flow from Financing is CHF-165 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF25.86 is trading 91.8% below its estimated GF Value™ of CHF314.46.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
Cash Flow from Financing: CHF-165 Mil
GF Value™: CHF314.46 vs. price of CHF25.86 (91.8% below fair value)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
72GF Score
Get the complete analysis for XSWX:AFX
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
